

Section 5: 510(k) Summary

SEP - 2 2011

## 510(k) Summary

**Prepared:** June 14, 2011

**Submitter/Holder:**

**Company Name:** CANON INC.  
**Company Address:** 30-2 Shimomaruko 3-chome, Ohta-ku  
Tokyo 146-8501, Japan  
**Contact Person:** Naoyasu Asaka  
**Phone Number:** 81-3-3758-2111  
**Fax Number:** 81-3-5482-3960

**Proposed Device:**

**Reason For 510(k):** New Model  
**Trade Name:** Canon  
**Model Name:** Digital Radiography CXDI-501G  
Digital Radiography CXDI-501C  
**Classification Name:** 90MQB, Solid State X-ray Imager  
**FDA 510(k) #:** To be assigned

**Predicate Device:**

**Trade Name:** Canon  
**FDA 510(k) #/Model Name:**  
K103591/ Digital Radiography CXDI-401G COMPACT/CXDI-401C COMPACT  
K091436/ Digital Radiography CXDI-55C  
K091435/ Digital Radiography CXDI-55G  
**Classification Name:** 90MQB, Solid State X-ray Imager

**Description of Device:**

The Digital Radiography CXDI-501G and CXDI-501C are solid state x-ray imagers which have 35.0 x 42.6 cm imaging area. The device intercepts x-ray photons and the scintillator emits visible spectrum photons that illuminate an array of photo-detectors that create an electrical signals. After the electrical signals are generated, it is converted to digital value, and the images will be displayed on monitors.

The CXDI-501G uses GOS (Gadolinium Oxy-Sulfide) as the material for fluorescent screen, while CXDI-501C uses CsI (Cesium Iodide) which provides high x-ray absorption as fluorescent screen. Both models employ housing for easy installation in stand and table unit.

**Intended Use:**

The Digital Radiography CXDI-501G and CXDI-501C provide digital image capture for conventional film/screen radiographic examinations. These devices are intended to replace radiographic film/screen systems in all general purpose diagnostic procedures. These devices are not intended for mammography applications.

**Comparison to Predicate:**

The imaging principle and intended use of the Digital Radiography CXDI-501G and CXDI-501C are the same as those of the predicate devices (Digital Radiography CXDI-401G COMPACT, CXDI-401C COMPACT, CXDI-55C or CXDI-55G).

K111682

Page 2 of 2

*Section 5: 510(k) Summary*

**Performance testing:**

The Electrical safety, Electromagnetic compatibility and other performance testings were performed on these devices which demonstrated that these devices are safe and effective, and are equivalent to the predicate devices.

**Conclusion:**

The Performance Data demonstrate that CXDI-501G and CXDI-501C are as safe and effective as the predicate devices (Digital Radiography CXDI-401G COMPACT, CXDI-401C COMPACT, CXDI-55C or CXDI-55G). Based on the information in this submission, similarity to the predicate devices, and the results of our design control activities and non-clinical testing, it is our opinion that the Digital Radiography CXDI-501G and CXDI-501C described in this submission are substantially equivalent to the predicate devices.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room – WO66-G609  
Silver Spring, MD 20993-0002

Mr. Naoyasu Asaka  
Staff manager  
Canon Inc.  
30-2 Shimomaruko 3-Chrome  
OHTA-KU TOKYO 146-8501  
JAPAN

AUG 23 2013

Re: K111682

Trade/Device Name: Canon/Digital Radiology, CXDI-501G/CXDI-501C  
Regulation Number: 21 CFR 892.1680  
Regulation Name: Stationary x-ray system  
Regulatory Class: II  
Product Code: MQB  
Dated: June 27, 2011  
Received: June 28, 2011

Dear Mr. Asaka:

This letter corrects our substantially equivalent letter of September 2, 2011.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely Yours,



Janine M. Morris  
Acting Director  
Division of Radiological Devices  
Office of In Vitro Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(K) Number (if known): 111682

Device Name: CXDI-501G and CXDI-501C

### Indications for Use:

DIGITAL RADIOGRAPHY CXDI-501G and CXDI-501C provide digital image capture for conventional film/screen radiographic examinations.

These devices are intended to replace radiographic film/screen systems in all general purpose diagnostic procedures.

These devices are not intended for mammography applications.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)

OR


Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation(ODE)

Page 1 of 1

  
\_\_\_\_\_  
Division Sign-Off  
Director of Radiological Devices  
Office of In vivo Diagnostic Device Evaluation and Safety

610K \_\_\_\_\_